BioAlliance Pharma SA (Paris:BIO) a specialty pharmaceutical company focused on the treatment of opportunistic infections, in cancer and HIV, announced the preliminary positive results for its US pivotal Phase III clinical trial with Loramyc™ (micon
Discuss Add this link to... Bury
Comments